{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:38:51Z","timestamp":1783359531449,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DA038886"],"award-info":[{"award-number":["U01DA038886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DA021525"],"award-info":[{"award-number":["U01DA021525"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DA038886"],"award-info":[{"award-number":["U01DA038886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Retention in substance use treatment is essential to treatment success. While programmatic factors are known to influence retention, less is known about the role of involuntary discharges from drug or alcohol treatment programs. Therefore, we sought to identify the prevalence of and factors associated with involuntary discharge due to ongoing substance use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were derived from two community-recruited prospective cohort studies of people who use drugs in Vancouver, Canada. Generalized estimating equation (GEE) analyses were used to identify variables associated with involuntary discharge from treatment programs due to ongoing substance use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between June 2017 and March 2020, 1487 participants who accessed substance use treatment and completed at least one study interview were included in this study. Involuntary discharge from a treatment program due to ongoing substance use was reported by 41 (2.8%) participants throughout the study, with 23 instances reported at baseline and another 18 reported during study follow-up. In a multivariable GEE analysis, involuntary discharge was positively associated with homelessness (Adjusted Odds Ratio [AOR]\u2009=\u20093.22, 95% Confidence Interval [95% CI]: 1.59\u20136.52), daily injection drug use (AOR\u2009=\u20091.87, 95% CI 1.06\u20133.32) and recent overdose (AOR\u2009=\u20092.50, 95% CI 1.38\u20134.53), and negatively associated with age (AOR\u2009=\u20090.93, 95% CI 0.90\u20130.96). In sub-analyses, participants have most commonly been discharged from in-patient treatment centres (52.2%), recovery houses (28.3%) and detox programs (10.9%), and for using heroin (45.5%) and\/or crystal methamphetamine (36.4%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>While involuntary discharge was a relatively rare occurrence, those who were discharged due to active substance use possessed several markers of risk, including high-intensity injection drug use, homelessness, and recent non-fatal overdose. Our findings highlight the need for increased flexibility within treatment programs to account for those who re-initiate or continue to use substances during treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01036-4","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T09:03:51Z","timestamp":1718960631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Involuntary discharge from drug or alcohol treatment programs in Vancouver, Canada"],"prefix":"10.1186","volume":"21","author":[{"given":"Kat","family":"Gallant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanna","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinCheol","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-J","family":"Milloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"1036_CR1","unstructured":"Federal provincial and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and stimulant-related Harms in Canada. Public Health Agency of Canada; December 2022. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"1036_CR2","unstructured":"Canadian Mental Health Association. Harm Reduction. 2022(September 19, 2022). https:\/\/ontario.cmha.ca\/harm-reduction\/"},{"issue":"9775","key":"1036_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","volume":"377","author":"BDLP Marshall","year":"2011","unstructured":"Marshall BDLP, Milloy MJM, Wood EP, Montaner JSGP, Kerr TP. Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: a retrospective population-based study. Lancet (British Edition). 2011;377(9775):1429\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(10)62353-7","journal-title":"Lancet (British Edition)"},{"issue":"3","key":"1036_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.drugalcdep.2013.03.024","volume":"1","author":"D Werb","year":"2013","unstructured":"Werb D, Kerr T, Buxton J, et al. Patterns of injection drug use cessation during an expansion of syringe exchange services in a Canadian setting. Drug Alcohol Depend Oct. 2013;1(3):535\u201340. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.03.024","journal-title":"Drug Alcohol Depend Oct"},{"issue":"1","key":"1036_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","volume":"25","author":"GJ MacArthur","year":"2014","unstructured":"MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy Jan. 2014;25(1):34\u201352. https:\/\/doi.org\/10.1016\/j.drugpo.2013.07.001","journal-title":"Int J Drug Policy Jan"},{"issue":"2","key":"1036_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","volume":"11","author":"IA Binswanger","year":"2007","unstructured":"Binswanger IA, Stern MF, Deyo RA, et al. Release from prison\u2013a high risk of death for former inmates. New Engl J Med Jan. 2007;11(2):157\u201365. https:\/\/doi.org\/10.1056\/NEJMsa064115","journal-title":"New Engl J Med Jan"},{"issue":"3","key":"1036_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/add.13200","volume":"111","author":"IA Binswanger","year":"2016","unstructured":"Binswanger IA, Stern MF, Yamashita TE, Mueller SR, Baggett TP, Blatchford PJ. Clinical risk factors for death after release from prison in Washington State: a nested case-control study. Addict Mar. 2016;111(3):499\u2013510. https:\/\/doi.org\/10.1111\/add.13200","journal-title":"Addict Mar"},{"key":"1036_CR8","doi-asserted-by":"publisher","unstructured":"Brinkley-Rubinstein L, Macmadu A, Marshall BDL et al. Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015. Drug and Alcohol Dependence. Apr 1. 2018;185:189\u2013191. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.12.014","DOI":"10.1016\/j.drugalcdep.2017.12.014"},{"issue":"4","key":"1036_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","volume":"1","author":"TC Green","year":"2018","unstructured":"Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration Fatal overdoses after implementing medications for Addiction Treatment in a Statewide Correctional System. JAMA Psychiatry Apr. 2018;1(4):405\u20137. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4614","journal-title":"JAMA Psychiatry Apr"},{"key":"1036_CR10","unstructured":"Public Health Ontario. Rapid review: strategies to mitigate risk of substance use-related harms during periods of disruption. 2020. https:\/\/www.publichealthontario.ca\/-\/media\/documents\/ncov\/he\/2020\/09\/mitigation-strategies-substance-use.pdf?la=en"},{"key":"1036_CR11","unstructured":"Canadian Centre on Substance Use and Addiction. Impacts of the COVID-19 pandemic on Substance Use Treatment Capacity in Canada. 2020. https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-12\/CCSA-COVID-19-Impacts-Pandemic-Substance-Use-Treatment-Capacity-Canada-2020-en.pdf"},{"issue":"2","key":"1036_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/10826084.2016.1267225","volume":"28","author":"H Matusow","year":"2018","unstructured":"Matusow H, Benoit E, Elliott L, Dunlap E, Rosenblum A. Challenges to Opioid Treatment Programs after Hurricane Sandy: patient and provider perspectives on Preparation, Impact, and recovery. Subst Use Misuse Jan. 2018;28(2):206\u201319. https:\/\/doi.org\/10.1080\/10826084.2016.1267225","journal-title":"Subst Use Misuse Jan"},{"issue":"5","key":"1036_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s11524-014-9904-5","volume":"91","author":"B McClure","year":"2014","unstructured":"McClure B, Mendoza S, Duncan L, Rotrosen J, Hansen H. Effects of regulation on methadone and buprenorphine provision in the wake of Hurricane Sandy. J Urban Health Oct. 2014;91(5):999\u20131008. https:\/\/doi.org\/10.1007\/s11524-014-9904-5","journal-title":"J Urban Health Oct"},{"issue":"3","key":"1036_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/ADM.0b013e31820497ae","volume":"5","author":"TP Condon","year":"2011","unstructured":"Condon TP, Jacobs P, Tai B, Pintello D, Miner L, Elcano JC. Patient relapse in the context of drug abuse treatment. J Addict Med Sep. 2011;5(3):157\u201362. https:\/\/doi.org\/10.1097\/ADM.0b013e31820497ae","journal-title":"J Addict Med Sep"},{"issue":"3","key":"1036_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02791072.2009.10400539","volume":"41","author":"HS Reisinger","year":"2009","unstructured":"Reisinger HS, Schwartz RP, Mitchell SG, et al. Premature discharge from methadone treatment: patient perspectives. J Psychoact Drugs Sep. 2009;41(3):285\u201396. https:\/\/doi.org\/10.1080\/02791072.2009.10400539","journal-title":"J Psychoact Drugs Sep"},{"issue":"1","key":"1036_CR16","first-page":"35","volume":"17","author":"IL Williams","year":"2020","unstructured":"Williams IL, Bonner E. Patient termination as the Ultimate failure of Addiction Treatment: Reframing Administrative Discharge as Clinical Abandonment. J Social Work Values Ethics. 2020;17(1):35.","journal-title":"J Social Work Values Ethics"},{"key":"1036_CR17","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Disaster planning handbook for behavioural health treatment programs. 2013. store.samhsa.gov\/sites\/default\/files\/d7\/priv\/sma13-4779.pdf"},{"issue":"6","key":"1036_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.280.6.547","volume":"280","author":"SA Strathdee","year":"1998","unstructured":"Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to Use of Free Antiretroviral Therapy in Injection Drug users. J Addict Med. 1998;280(6):547\u20139. https:\/\/doi.org\/10.1001\/jama.280.6.547","journal-title":"J Addict Med"},{"issue":"5","key":"1036_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jama.300.5.550","volume":"6","author":"E Wood","year":"2008","unstructured":"Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. J Am Med Association Aug. 2008;6(5):550\u20134. https:\/\/doi.org\/10.1001\/jama.300.5.550","journal-title":"J Am Med Association Aug"},{"key":"1036_CR20","unstructured":"Government of British Columbia. Recovery services and treatment support. Accessed August 21. 2023, https:\/\/www2.gov.bc.ca\/gov\/content\/overdose\/what-you-need-to-know\/recovery-services-treatment-support"},{"key":"1036_CR21","unstructured":"BC Housing. Addiction Recovery Program. Accessed August 21. 2023, https:\/\/www.bchousing.org\/housing-assistance\/housing-with-support\/addiction-recovery-program"},{"key":"1036_CR22","unstructured":"Substance Abuse and Mental Health Services Administration OotSG. Chapter 4 early intervention, treatment and management of Substance Use disorders. US Department of Health and Human Services; 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK424859\/"},{"issue":"3","key":"1036_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2648.1994.tb02382.x","volume":"20","author":"AP Boyes","year":"1994","unstructured":"Boyes AP. Repetition of overdose: a retrospective 5-year study*. J Adv Nurs. 1994;20(3):462\u20138. https:\/\/doi.org\/10.1111\/j.1365-2648.1994.tb02382.x","journal-title":"J Adv Nurs"},{"issue":"2","key":"1036_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/00952990.2017.1306747","volume":"03","author":"M Galanter","year":"2018","unstructured":"Galanter M. Combining medically assisted treatment and twelve-step programming: a perspective and review. Am J Drug Alcohol Abus. 2018;03(2):151\u20139. https:\/\/doi.org\/10.1080\/00952990.2017.1306747. \/04 2018.","journal-title":"Am J Drug Alcohol Abus"},{"issue":"2","key":"1036_CR25","first-page":"229","volume":"23","author":"SW Hwang","year":"2001","unstructured":"Hwang SW. Homelessness and health. CMAJ Jan. 2001;23(2):229\u201333.","journal-title":"CMAJ Jan"},{"key":"1036_CR26","doi-asserted-by":"publisher","unstructured":"Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. The Lancet. 2014\/10\/25\/ 2014;384(9953):1529\u20131540. https:\/\/doi.org\/10.1016\/S0140-6736(14)61132-6","DOI":"10.1016\/S0140-6736(14)61132-6"},{"key":"1036_CR27","doi-asserted-by":"publisher","unstructured":"Doran KM, Rahai N, McCormack RP et al. Substance use and homelessness among emergency department patients. Drug and Alcohol Dependence. 2018\/07\/01\/2018;188:328\u2013333. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.04.021","DOI":"10.1016\/j.drugalcdep.2018.04.021"},{"key":"1036_CR28","doi-asserted-by":"crossref","unstructured":"Stablein GW, Hill BS, Keshavarz S, Llorente MD. Homelessness and Substance Use disorders. In: Ritchie EC, Llorente MD, editors. Clinical management of the homeless patient: Social, Psychiatric, and Medical issues. Springer International Publishing; 2021. pp. 179\u201394.","DOI":"10.1007\/978-3-030-70135-2_12"},{"key":"1036_CR29","doi-asserted-by":"publisher","unstructured":"Nilsson SF, Nordentoft M, Fazel S, Laursen TM. Homelessness and police-recorded crime victimisation: a nationwide, register-based cohort study. The Lancet Public Health. 2020\/06\/01\/2020;5(6):e333-e341. https:\/\/doi.org\/10.1016\/S2468-2667(20)30075-X","DOI":"10.1016\/S2468-2667(20)30075-X"},{"issue":"3","key":"1036_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/ije\/dyp160","volume":"38","author":"DS Morrison","year":"2009","unstructured":"Morrison DS. Homelessness as an independent risk factor for mortality: results from a retrospective cohort study. Int J Epidemiol Jun. 2009;38(3):877\u201383. https:\/\/doi.org\/10.1093\/ije\/dyp160","journal-title":"Int J Epidemiol Jun"},{"issue":"4","key":"1036_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/ADM.0b013e318155980e","volume":"1","author":"GE Woody","year":"2007","unstructured":"Woody GE, Kane V, Lewis K, Thompson R. Premature deaths after discharge from methadone maintenance: a replication. J Addict Med Dec. 2007;1(4):180\u20135. https:\/\/doi.org\/10.1097\/ADM.0b013e318155980e","journal-title":"J Addict Med Dec"},{"key":"1036_CR32","unstructured":"NAADAC tAfAP. NAADAC\/NCC AP Code of Ethics. 2021. https:\/\/www.naadac.org\/assets\/2416\/naadac_code_of_ethics_112021.pdf"},{"key":"1036_CR33","unstructured":"Canadian Mental Health Association. Harm Reduction. Accessed November 17. 2022, https:\/\/ontario.cmha.ca\/harm-reduction\/"},{"issue":"1","key":"1036_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4102\/phcfm.v12i1.2285","volume":"6","author":"A Scheibe","year":"2020","unstructured":"Scheibe A, Shelly S, Hugo J, et al. Harm reduction in practice - the community oriented Substance Use Programme in Tshwane. Afr J Prim Health Care Fam Med. May 2020;6(1):e1\u20136. https:\/\/doi.org\/10.4102\/phcfm.v12i1.2285","journal-title":"Afr J Prim Health Care Fam Med"},{"issue":"1","key":"1036_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/phcfm.v15i1.3392","volume":"15","author":"DS Goeieman","year":"2023","unstructured":"Goeieman DS, Nonyane DS, Nzaumvila, Doudou K, van Rensburg MNS, Janse. Retention of service users on opioid substitution therapy in the City of Tshwane, South Africa. Afr J Prim Health Care Family Med. 2023;15(1):1\u201310. https:\/\/doi.org\/10.4102\/phcfm.v15i1.3392","journal-title":"Afr J Prim Health Care Family Med"},{"issue":"1","key":"1036_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-7517-9-5","volume":"2012\/01\/19","author":"TE Wright","year":"2012","unstructured":"Wright TE, Schuetter R, Fombonne E, Stephenson J, Haning WF. Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. Harm Reduct J. 2012;2012\/01\/19(1):5. https:\/\/doi.org\/10.1186\/1477-7517-9-5","journal-title":"Harm Reduct J"},{"issue":"1","key":"1036_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jsat.2006.07.004","volume":"32","author":"ND Berkman","year":"2007","unstructured":"Berkman ND, Wechsberg WM. Access to treatment-related and support services in methadone treatment programs. J Subst Abuse Treat Jan. 2007;32(1):97\u2013104. https:\/\/doi.org\/10.1016\/j.jsat.2006.07.004","journal-title":"J Subst Abuse Treat Jan"},{"key":"1036_CR38","doi-asserted-by":"publisher","unstructured":"Englander H, Dobbertin K, Lind BK, et al. Inpatient Addiction Medicine Consultation and Post-hospital Substance Use Disorder Treatment Engagement: a propensity-matched analysis. J Gen Intern Med. Dec 2019;34(12):2796\u2013803. https:\/\/doi.org\/10.1007\/s11606-019-05251-9","DOI":"10.1007\/s11606-019-05251-9"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01036-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01036-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01036-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T09:09:02Z","timestamp":1718960942000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01036-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01036-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies from which the data is derived (VIDUS and ACCESS) have received approval from the University of British Columbia\/Providence Health Care Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"US National Institutes of Health (U01DA038886, U01DA021525).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sources of support"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}